Real-World Study of Guselkumab Treatment for Psoriatic Arthritis Using Ultrasound to Measure Effectiveness

What this Trial Is About

Researchers are evaluating how well guselkumab works to improve symptoms of psoriatic arthritis, an inflammatory joint disease affecting people with psoriasis, by using musculoskeletal ultrasound MSUS in a real-world setting. This observational study aims to collect data from routine clinical practice to better understand treatment effects in participants who have active psoriatic arthritis and meet specific clinical and imaging criteria. Participants with a confirmed diagnosis of psoriatic arthritis who are treated with guselkumab according to their usual clinical care will be enrolled. No study drug is provided by the trial instead, the study collects data available from standard care, including ultrasound exam results. Participants will be asked about their health and well-being during the study. The study includes baseline and follow-up assessments up to 52 weeks to monitor disease activity and response to treatment. During the study, participants will undergo musculoskeletal ultrasound evaluations and clinical assessments at various time points, including baseline, week 12, week 24, and week 52. Researchers will track outcomes such as reduction in synovitis scores, disease activity indexes, pain levels, physical function, and treatment persistence. The study also monitors adverse events. Participation involves routine clinical visits and data collection over approximately one year to observe guselkumab treatment effects in real-world use.

A Study of Guselkumab in Participants With Psoriatic Arthritis (PsA) in a Real-World Setting